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 2 
Abstract 22 
Tart Montmorency cherry concentrate (MC) has been reported to attenuate the symptoms of 23 
exercise-induced muscle damage (EIMD) and to accelerate exercise recovery, which has been 24 
attributed to its high anti-inflammatory and antioxidant properties. Although these data are 25 
promising, there are no data regarding exclusively female populations. Therefore, the aim of 26 
this investigation was to examine the efficacy of MC on recovery following EIMD in females. 27 
In a randomised, double-blind, placebo-controlled study, twenty physically active females 28 
(mean ± SD age 19 ± 1 y; stature 167 ± 6 cm; body mass 61.4 ± 5.7 kg) consumed MC or a 29 
placebo (PL) for eight days (30 mL twice per day). Following four days of supplementation, 30 
participants completed a repeated-sprint protocol and measures of muscle soreness (DOMS), 31 
pain pressure threshold (PPT), limb girth, flexibility, muscle function, and systemic indices of 32 
muscle damage and inflammation were collected pre, immediately post (0 h) and 24, 48 and 33 
72 h post-exercise. Time effects were observed for all dependent variables (p<0.05) except 34 
limb girth and high sensitivity C-reactive protein. Recovery of countermovement jump height 35 
was improved in the MC group compared to PL (p=0.016). There was also a trend for lower 36 
DOMS (p=0.070) and for higher PPT in the MC group at the rectus femoris (p=0.071). The 37 
data demonstrate that MC supplementation may be a practical nutritional intervention to help 38 
attenuate the symptoms of muscle damage and improve recovery on subsequent days in 39 
females.  40 
Key words 41 
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Introduction 43 
Initial muscle damage is thought to be caused by a combination of mechanical disruption to 44 
the myofibrils and oxidative stress; the latter owing to an increase in the production of reactive 45 
oxygen and nitrogen species (RONS) and nitric oxide (NO) derivatives which may exceed 46 
antioxidant capacity (Powers & Jackson, 2008). Moreover, the secondary inflammatory 47 
response to muscle injury involves the degradation of damaged muscle by immune cells which 48 
release pro-inflammatory cytokines and further RONS and NO derivatives; exacerbating 49 
muscle damage (Clarkson & Hubal, 2002). The role of RONS and NO derivatives in the 50 
oxidative stress, inflammatory, and muscle damage responses which manifest during and 51 
following exercise has raised substantial interest in antioxidant supplementation. Of particular 52 
interest is tart Montmorency cherry concentrate (MC), which has been proposed to be an 53 
effective recovery aid due to its high anti-inflammatory and antioxidant properties (Bell et al., 54 
2014; Bell et al., 2015; Keane et al., 2015a; Kirakosyan et al., 2015; Seeram et al., 2001; Wang 55 
et al., 1999). Montmorency tart cherries and their derivatives contain numerous polyphenols 56 
that include flavonoids; for example, the flavonol quercetin and anthocyanins (Kim et al., 2005; 57 
Kirakosyan et al., 2009). Certainly, the polyphenolic compounds that MC contain result in 58 
higher oxygen radical absorbance capacity (ORAC) values compared to several other 59 
antioxidant beverages such as Concord grape, acai, and blueberry juice (Bell et al., 2013; 60 
Howatson et al., 2010; Seeram et al., 2008).  61 
To date, research in exercise and recovery paradigms has demonstrated that MC can improve 62 
recovery from damaging bouts of exercise in isolated muscle groups by attenuating decrements 63 
in muscle strength and/or soreness and pain (Bowtell et al., 2011; Connolly et al., 2006; Levers 64 
et al., 2015). Additionally, following damaging running activity, research has identified MC to 65 
be beneficial in reducing pain (Kuehl et al., 2010) and improving indices of inflammation, 66 
oxidative stress, antioxidant status and muscle function (Howatson et al., 2010). More recently, 67 
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MC has also been shown to facilitate recovery following cycling (Bell et al., 2014; Bell et al., 68 
2015) and an adapted Loughborough Intermittent Shuttle Test (LIST) protocol (Bell et al., 69 
2016).  70 
Collectively, these lines of investigation have application to athletic populations that would 71 
benefit from reduced symptoms of muscle damage following strenuous activity. However, the 72 
effects of MC beyond isolated muscle, running and cycling activity are limited, and 73 
conceptually other sports and activities could benefit from this intervention. In addition, whilst 74 
females have been included in mixed-sex populations (Howatson et al., 2010; Kuehl et al., 75 
2010), there are no data regarding exclusively female populations, largely due to the potential 76 
for oestrogen to influence outcome variables (Kendall & Eston, 2002). A growing body of 77 
evidence suggests that oestrogen has antioxidant properties (Tiidus et al., 2005; Wolf et al., 78 
2012) and may help to maintain muscle membrane integrity consequent to muscle damage. As 79 
a result, the initial physiological stress and ensuing recovery associated with exercise-induced 80 
muscle damage (EIMD) in females is likely to differ compared to male populations. Indeed, 81 
recent evidence suggests that EIMD and recovery may differ between menstrual cycle phases 82 
given the fluctuating oestrogen concentrations (Markofski & Braun, 2014). Moreover, given 83 
their structural similarities to oestrogen, polyphenolic secondary plant metabolites (including 84 
the flavonoids that MC contains) appear to exert oestrogenic effects (Miksicek, 1995), and thus 85 
modulate and affect the bioavailability of endogenous oestrogens (Ward & Kuhnle, 2010). As 86 
such, since oestrogen is thought to play a key role in the observed sex differences in EIMD, 87 
currently the lack of studies investigating the supplementation of MC in a female only 88 
population is surprising and warrants research.  89 
Therefore, the aim of this investigation was to examine the efficacy of MC on recovery from 90 
EIMD in females. It was hypothesised that indices of EIMD would be attenuated by the 91 




Twenty physically active females (mean ± SD age 19 ± 1 y; stature 167 ± 6 cm; body mass 95 
61.4 ± 5.7 kg; BMI 22.1 ± 1.9 kg·m-2) were recruited from a university dance team and gave 96 
written informed consent. The sample size was determined by completing a power analysis 97 
(power=0.8, α=0.05) based on isometric strength data from Bowtell et al. (2011). This 98 
determined a sample size of five in each group would provide statistical power above 80%, 99 
with an alpha level of 0.05. Exclusion criteria were; epilepsy, bronchitis, severe asthma, cardiac 100 
complaints, bacterial or viral infection in the 2 weeks preceding, injury or recovering from an 101 
injury sustained in the preceding 4 weeks, pregnancy, food allergy relating to the study 102 
supplements (as discussed with the investigator), or anything that may prevent them from 103 
successfully completing the study that was described. Participants had been training in dance 104 
regularly for 13 ± 4 years and were currently exercising for 8.3 ± 5 h per week; with no 105 
significant differences between groups (independent samples t-test p=0.567 and p=0.598, 106 
respectively). A single self-reported menstrual cycle questionnaire (as used previously by 107 
Brown et al., 2016a) identified the current contraceptive use of participants; nine were using 108 
an oral combination pill (all monophasic; n=6 in Montmorency cherry concentrate (MC) group 109 
and n=3 in placebo (PL) group), six were using a progesterone only pill/implant/injection (n=3 110 
in both MC and PL groups), and five were menstruating normally (n=1 in MC group and n=4 111 
in PL group). This also estimated menstrual cycle phase and allowed testing days to be 112 
assigned; all data collection took place during the early to mid-luteal phase, or where applicable 113 
in the 14 days before a withdrawal bleed. For 24 h prior to, and for each of the testing days, 114 
participants were asked to avoid strenuous exercise, alcohol, caffeine, nutritional supplements, 115 
and any anti-inflammatory drugs or alternative treatments. Participants completed a weighed 116 
food diary (analysed using dietary analysis software (Nutritics Ltd, Swords, Ireland)) and 117 
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activity log throughout all trial periods. Aside from the restrictions outlined previously, 118 
participants were not restricted in their consumption of polyphenolic rich foods and were 119 
instructed to consume their habitual diets. However, portions of foods thought to contain 120 
antioxidants were totalled for each day and averaged across the experimental period (Howatson 121 
et al., 2012; Howatson et al., 2010). The study was conducted according to the guidelines of 122 
the Declaration of Helsinki and all experimental procedures were approved by the Faculty of 123 
Health and Life Sciences Ethics Committee at the University of Northumbria.  124 
Experimental protocol 125 
Participants were allocated to either tart Montmorency cherry concentrate (MC; n=10) or 126 
placebo (PL; n=10) supplementation in a double-blind manner using stratified randomisation 127 
to ensure that groups were matched and counterbalanced for muscle function. A pre-128 
supplementation blood sample (baseline) was taken in order to detect any changes in total 129 
creatine kinase (CK) and high sensitivity C-reactive protein (hsCRP) with preload 130 
supplementation. Participants fasted for ≥10 h prior to each visit, except for water (consumed 131 
ad libitum) and the morning supplement. On arrival at the laboratory, baseline measures of 132 
dependant variables were recorded. Participants completed the exercise protocol, and after a 2 133 
min rest, measurement of dependent variables was repeated. Before leaving the laboratory, 134 
participants were reminded to consume a supplement prior to their evening meal. 135 
Supplementation and measurement of dependent variables were then repeated at the same time 136 
of day (± 1 h) for the following 3 days (24, 48 and 72 h post EIMD). 137 
Supplementation 138 
Participants consumed their habitual diets during all trial periods. Participants were provided 139 
with eight days of supplementation along with instructions on ingestion frequency and timing. 140 
This period was for four days prior to muscle-damaging exercise, the day of exercise, and for 141 
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three days of recovery. The daily dose was two servings of the MC or PL; one dose taken prior 142 
to breakfast (or 1-2 h prior to laboratory visits), and one dose prior to evening meal (except for 143 
the final day where only one supplement was consumed before the final visit). This is based on 144 
previous work showing a positive effect on recovery following strenuous exercise (Bell et al., 145 
2016; Bell et al., 2014; Bell et al., 2015).  146 
The MC beverage was prepared with 30 mL of concentrate (CherryActive, Sunbury, UK) 147 
diluted in 100 mL of water. According to the manufacturer’s information, a 30 mL dose of 148 
concentrate is equivalent to approximately 90 whole cherries and has been previously reported 149 
to contain a total anthocyanin content of 73.5 mg·L−1 of cyanidin-3-glucoside, a total phenolic 150 
content of 178.8 gallic acid equivalent·L−1 and an antioxidant capacity (TEAC) of 0.58 trolox 151 
equivalents·L−1 (Keane et al., 2016).  The PL was prepared with 25 mL of a synthetically 152 
derived fruit flavoured concentrate with negligible phytochemical content (Kia-Ora, Uxbridge, 153 
UK) in 100 mL of water and was fortified with flavourless maltodextrin (Myprotein, 154 
Manchester, UK) and flavourless whey protein powder (Arla Foods, Amba, Denmark). This 155 
was in order to match test beverages as closely as possible for volume (130 ml), consistency, 156 
colour, and macronutrient (24.5 g carbohydrate and 1.1 g protein) and energy content (102 kcal 157 
and 103 kcal for the MC and PL beverages, respectively).   158 
Exercise protocol 159 
Following a standardised warm up, participants completed a repeated-sprint protocol which 160 
comprised 15 x 30 m maximal sprints with a rapid 10 m deceleration phase, each separated by 161 
60 s rest (Brown et al., 2016a; Brown et al., 2016b; Howatson & Milak, 2009; Keane et al., 162 
2015b). Rate of perceived exertion (RPE; Borg, (1982)) and heart rate (HR; Model RS-400, 163 
Polar, Kempele, Finland) were collected after each sprint effort. Sprint times were recorded 164 
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using timing gates (Brower telemetric timers, Brower timing systems, Draper, USA) to 165 
determine total sprint time, mean sprint time, and rate of fatigue (Fitzsimons et al., 1993).  166 
 167 
Dependant variables 168 
Muscle soreness 169 
Subjective ratings of muscle soreness (DOMS) were measured using a 200 mm visual analogue 170 
scale. Participants were required to indicate the level of perceived active lower limb soreness 171 
felt during a 900 squat. Pain pressure threshold (PPT) was measured with a digital algometer 172 
(Model FDX, Wagner Instruments, Greenwich, USA) at three muscle locations on the right 173 
leg; the rectus femoris (RF), the vastus lateralis (VL), and medial head of the gastrocnemius 174 
(GM) (Clifford et al., 2016). To determine PPT, participants were asked to verbally indicate 175 
when the pressure applied to the muscle (at an approximate rate of 5 N·s-1) became too 176 
uncomfortable to tolerate. Intra-trial and inter-trial percentage coefficient of variation (%CV) 177 
were <8% for all locations.  178 
Limb girth 179 
An anthropometric tape measure (Bodycare Products, Warwickshire, United Kingdom) was 180 
used to determine calf (measured at its largest girth at baseline) and mid-thigh (located as 181 
midway between the inguinal fold and the superior border of the patella) girths of the right leg. 182 
Calf and mid-thigh girth intra-examiner %CVs were <1%. 183 
Flexibility 184 
Hamstring stiffness and flexibility was measured using the sit and reach test. The knees were 185 
fully extended with the feet together against the sit and reach box. Participants were instructed 186 
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to stretch as far as possible (but not to the point of pain) and to hold their ‘best stretch’ for 187 
approximately 2 s (American College of Sports Medicine, 2013) (recorded to the nearest 0.5 188 
cm). Intra-trial and inter-trial %CV were <5%. 189 
 190 
Muscle function 191 
Participants completed three countermovement jumps (CMJ) and three drop jumps (for 192 
measurement of reactive strength index (RSI)) using a light timing system (Optojump, 193 
Microgate, Bolzano, Italy), keeping their hands on their hips throughout. For CMJ, participants 194 
were asked to squat down and jump vertically and maximally. For RSI (jump height (cm) ÷ 195 
ground contact time (s)), participants were instructed to drop from a height of 30 cm and upon 196 
landing, to perform a two-footed jump maximally with minimum contact time. Each effort was 197 
separated by 60 s rest and the peak CMJ and RSI were used for analysis. Intra-trial and inter-198 
trial %CV were both <4% and <12% for CMJ and RSI respectively. 199 
Maximum voluntary isometric contraction (MVC) of the right knee extensors was measured 200 
using a strain gauge (MIE Digital Myometer, MIE Medical Research Ltd, Leeds, UK). While 201 
in a seated position, the knee joint angle was standardised at 900 of flexion before each 202 
contraction. The peak force (Newtons, N) of three MVCs (of 3 s duration interspersed with 30 203 
s rest) was used for analysis. Intra-trial and inter-trial %CV were <4%.    204 
Participants completed a single maximal effort 30 m sprint, and sprint time was recorded 205 
(Brower telemetric timers, Brower timing systems, Draper, USA). Both intra-trial and inter-206 
trial %CV were <2%.   207 
Blood sampling and analysis 208 
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Blood samples (10 mL) were collected via venepuncture from the antecubital fossa area into 209 
serum gel vacutainers. Samples were rested at room temperature for 20 min, and centrifuged 210 
for 15 min (4˚C) at 3000 RCF (Allegra X-22 Centrifuge, Beckman Coulter, Bucks, UK). 211 
Aliquots of serum were stored at -80°C for later analysis of CK and hsCRP; determined 212 
spectrophotometrically using an automated system (Roche Modular, Roche Diagnostics, 213 
Burgess Hill, UK). Due to technical issues, 5 blood samples (<5%) were not collected. When 214 
lower detection limits were not reached for hsCRP, the lowest detectable concentration was 215 
used (0.15 mg·L-1). Inter-assay and intra-assay %CV for both total CK and hsCRP were <9%. 216 
Statistical analysis 217 
For the purpose of data analysis, all dependant variables except for DOMS, CK and hsCRP are 218 
expressed as a percentage relative to pre muscle damage values to account for inter-individual 219 
variability. Statistical software (IBM Statistical Package for Social Sciences (SPSS) V22 IBM, 220 
Armonk, USA) was used for inferential analysis and statistical significance accepted at the 221 
p≤0.05 level a priori. Mixed factor repeated-measures analysis of variance were performed for 222 
each dependent variable. Mauchly’s test assessed the sphericity of the data and, where 223 
appropriate, violations were corrected using the Greenhouse–Geisser correction. Significant 224 
main effects were analysed using the Least Significant Difference test for adjustment for 225 
multiple comparisons. Paired samples t-tests were conducted to assess differences between 226 
total CK and hsCRP levels pre-supplementation (baseline) and pre-exercise, in order to detect 227 
any changes in systemic indices with preload supplementation. Independent samples t-tests 228 
were conducted on peak HR, peak RPE, fatigue, and total and mean sprint time to examine 229 
differences in exercise intensity during the repeated-sprint protocol between groups. Where 230 
appropriate, Cohen’s d effect sizes (ES) were calculated with the magnitude of effects 231 




There were no differences in the total energy intake and macronutrient intake presented as a 235 
percentage of total energy intake (all p>0.05, ES>0.47), and the number of portions of foods 236 
containing antioxidants consumed by participants in both treatment groups (6 ± 2 in both MC 237 
and PL groups; p=0.731) during the supplementation period. Following all data collection 238 
periods, only n=4 participants correctly identified which supplement they had consumed. There 239 
were no differences between MC and PL groups for total (80.74 ± 4.02 vs 81.69 ± 3.67 s) and 240 
mean (5.38 ± 0.27 vs 5.45 ± 0.24 s) sprint time, fatigue (5.23 ± 2.02 vs 4.54 ± 2.16%), peak 241 
HR (176 ± 15 vs 178 ± 8 bpm), and peak RPE (17 ± 2 vs 18 ± 1) during the repeated-sprint 242 
protocol (all p>0.05); demonstrating that the exercise stimulus was comparable between 243 
groups. All raw data not illustrated in figures are presented in Table 1.  244 
Muscle soreness increased post-exercise (p<0.001), peaking at 24 h and remained elevated 245 
throughout recovery in both groups (Figure 1); however, there was a trend and moderate effect 246 
for lower DOMS in the MC group (p=0.070, ES=0.58). At all three locations, PPT was reduced 247 
post-exercise (all p<0.001), reached lowest levels at 24 h and then increased throughout 248 
recovery. There were no group differences in PPT at the VL or GM, but a trend and moderate 249 
effect for higher PPT in the MC group at the RF was observed (p=0.071, ES=0.59). 250 
Thigh and calf girths were unaffected post-exercise and there were no differences between 251 
treatment groups (all p>0.05).  Flexibility was reduced for 48 h post-exercise but returned to 252 
baseline levels at 72 h in both groups (p=0.022) with no group differences.  253 
All measures of muscle function (CMJ, RSI, MVC and 30 m sprint time) were reduced post-254 
exercise and progressively recovered throughout recovery (all p<0.05). While recovery of these 255 
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measures appeared to accelerate with MC, a group effect was only evident with CMJ (p=0.016, 256 
ES=0.66) (Figure 2).  257 
Total CK and hsCRP concentrations were not different between baseline and pre-exercise time-258 
points for both MC and PL groups (all p>0.05). Both groups experienced an increase in 259 
circulating CK, which peaked 24 h post-exercise and remained elevated for 72 h post-exercise 260 
(p<0.001) with no differences between groups (Figure 3). Circulating hsCRP was unaffected 261 
by exercise and was not different between groups.  262 
 263 
Discussion 264 
This study sought to examine the efficacy of 8-day MC supplementation on recovery from 265 
EIMD in females. The data demonstrate that MC supplementation accelerated the recovery of 266 
CMJ and was associated with trends of reduced muscle soreness.  267 
The clear acceleration in recovery of CMJ following MC supplementation supports a recent 268 
study demonstrating an improvement in CMJ (Bell et al., 2016), and a number of studies 269 
demonstrating an accelerated recovery in other measures of muscle function with MC 270 
consumption (Bell et al., 2015; Bowtell et al., 2011; Connolly et al., 2006; Howatson et al., 271 
2010). The improvement of CMJ with MC may be explained by a protection against oxidative 272 
injury to the type II fibres recruited for such activity. Eccentric exercise is thought to 273 
preferentially damage type II muscle fibres (Macaluso et al., 2012) and this has implications 274 
on the muscles’ force-generating capacity (Byrne et al., 2004). Interestingly, evidence suggests 275 
that mitochondrial ROS production and/or release is potentiated in type II fibres (Anderson & 276 
Neufer, 2006) and the activity of endogenous antioxidant enzymes including superoxide 277 
dismutase (SOD) (Criswell et al., 1993; Powers et al., 1994) and glutathione peroxidase (GPX) 278 
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(Lawler et al., 1994; Powers et al., 1994) are lower compared with type I fibres in rodent 279 
models. During periods of increased oxidant production (for instance intense exercise), both 280 
enzymatic and non-enzymatic antioxidants collectively provide some protection to muscle 281 
fibres from oxidative injury (Powers & Jackson, 2008). Therefore, conceptually the 282 
supplementation of non-enzymatic antioxidants contributed to the free radical scavenging 283 
capacity of type II fibres and facilitated recovery of CMJ. However, the functional measures 284 
in the present investigation all require type II fibre recruitment, so intuitively, we would have 285 
expected the measures to be equally affected by MC. Indeed, the lack of an accelerated 286 
recovery of MVC with MC is in contrast to a number of previous studies (Bell et al., 2015; 287 
Bowtell et al., 2011; Connolly et al., 2006; Howatson et al., 2010). Certainly, the role of MC 288 
in accelerating the recovery of muscle function in this population following EIMD in the 289 
current study remains unclear.   290 
Supplementation with MC resulted in a moderate effect for reductions in DOMS and increases 291 
in PPT at the RF; which could have played a role in the observed improvements in CMJ. This 292 
is in line with a number of investigations reporting reduced soreness and pain with MC 293 
supplementation (Bell et al., 2016; Connolly et al., 2006; Kuehl et al., 2010; Levers et al., 294 
2015). However, these reductions previously reported have not always been accompanied with 295 
improvements in muscle function, and vice versa (Bell et al., 2015; Bowtell et al., 2011; Levers 296 
et al., 2015), and others have found no reduction in DOMS with MC consumption (Bell et al., 297 
2015; Bowtell et al., 2011; Howatson et al., 2010). The inconsistencies in the literature could 298 
be explained by the disparities in exercise protocol employed. Indeed, muscle soreness has 299 
been associated with increases in inflammation following exercise (Kraemer et al., 2004). In 300 
the current investigation, hsCRP was not different between groups, and limb girth (an indirect 301 
measure of inflammation, swelling and oedema (Smith, 1991)) was unaffected by the exercise. 302 
Compared to marathon running (Howatson et al., 2010) and high intensity cycling exercise 303 
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(Bell et al., 2015), where CRP has been shown to increase 24 and 48 h post-exercise, the 304 
repeated-sprint protocol does not appear to induce a large inflammatory response. It is 305 
conceivable that the exercise stimulus was insufficient to detect larger magnitudes of change 306 
in soreness and PPT with MC. Similarly, the CK values elicited by the exercise protocol in the 307 
current study are lower than other damaging protocols, suggesting a moderate muscle damage 308 
response, and likely influencing the ability to demonstrate differences. In addition, females 309 
have been shown to demonstrate lower basal circulating concentrations of CK, and a lower CK 310 
response following exercise compared to males (Wolf et al., 2012), owing in part to the 311 
antioxidant properties of oestrogen (Tang, Abplanalp, Ayres, & Subbiah, 1996).  312 
The data which demonstrate no group differences in hsCRP and CK do not wholly support the 313 
literature which traditionally suggests attenuated symptoms of EIMD with MC is attributable 314 
to reduced muscle damage and inflammation; at least following repeated-sprint exercise in 315 
females. However, the current study was limited by a lack of measurement of oxidative stress 316 
and antioxidant capacity. Indeed, some have identified differences in oxidative stress and 317 
antioxidant status following strenuous exercise with supplementation of MC compared to PL 318 
(Bell et al., 2014; Bowtell et al., 2011; Howatson et al., 2010). It is possible that this is 319 
magnified in females given that oestrogen is also thought to have antioxidant properties (Tiidus 320 
et al., 2005; Wolf et al., 2012) as oestrogens, similar to vitamin E, display a hydroxyl group on 321 
their phenolic ring (Tiidus et al., 2001). It is thought that oestrogen donates the hydrogen atom 322 
to lipid peroxyl radicals, limiting lipid peroxidation in the cell membrane (Kendall & Eston, 323 
2002). Perhaps enhanced antioxidant status and redox balance may have contributed to the 324 
improvements in CMJ and trends in reduced soreness observed with MC in this study. Future 325 
research should include measurement of a variety of systemic indices to provide greater insight 326 
into specific mechanisms influencing improved muscle function and pain with MC. Moreover, 327 
more accurate determination of menstrual cycle phase (urine ovulation prediction tests for 328 
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example) and measurement of concentrations of oestrogen (particularly of oestradiol) in female 329 
participants is warranted to assist with the interpretation of results.   330 
This study demonstrated that 8-day MC supplementation alongside a habitual diet improved 331 
recovery of CMJ and tended to lower muscle soreness compared to PL. This research adds to 332 
the existing body of knowledge whilst providing new information for the potential application 333 
of MC to wider groups. In particular, it would appear that female populations might benefit 334 
from this nutritional intervention to help attenuate the symptoms of EIMD and improve 335 
recovery on subsequent days. 336 
 337 
  338 
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Time post muscle-damaging exercise (h) 
Pre 0 24 48 72 
RF PPT, 
N 
MC  48.1 ± 8.8  46.9 ± 11.6 42.5 ± 10.8 48.7 ± 12.9 56.0 ± 17.5 
 PL 35.2 ± 12.4 30.8 ± 10.6  25.9 ± 6.9 28.7 ± 10.0  35.1 ± 8.8 
VL PPT, 
N 
MC  42.6 ± 9.8 47.3 ± 18.0 34.9 ± 13.6 41.6 ± 12.6 53.3 ± 23.3 
 PL 30.2 ± 10.1 29.7 ± 11.8 25.5 ± 7.2 28.5 ± 10.2 32.5 ± 10.5 
GM PPT, 
N 
MC 41.4 ± 11.2 42.4 ± 15.5 31.8 ± 8.8 39.4 ± 9.4 50.2 ± 12.2 
 PL 27.3 ± 12.1 25.0 ± 12.1 21.9 ± 8.7 24.9 ± 10.2 30.1 ± 9.9 
Thigh 
girth, cm 
MC 50.1 ± 3.1 50.4 ± 3.0 50.3 ± 3.0 50.3 ± 3.0 50.3 ± 2.8 
PL 50.6 ± 2.2 50.9 ± 2.6 51.0 ± 2.4 51.0 ± 2.5 50.9 ± 2.4 
Calf girth, 
cm 
MC 36.1 ± 2.3 36.2 ± 2.4 36.1 ± 2.4 36.1 ± 2.3 36.2 ± 2.2 
PL 36.2 ± 2.1 36.1 ± 1.9 36.2 ± 2.0 36.2 ± 2.2 36.2 ± 2.0 
Flexibility
, cm 
MC 29.1 ± 5.4 28.3 ± 6.4 25.0 ± 7.2 26.4 ± 9.3 29.0 ± 7.8 
 23 
 PL 20.3 ± 9.0 17.7 ± 9.0 14.5 ± 6.1 17.4 ± 8.3 17.6 ± 9.0 
RSI, cm·s-
1 
MC 102.8 ± 
22.5 
88.6 ± 21.5 97.2 ± 28.5 99.0 ± 22.2 
 107.0 ± 
27.1 
 PL 81.5 ± 17.6 74.7 ± 13.7 72.0 ± 13.8 73.0 ± 14.4 80.2 ± 20.1 
























5.32 ± 0.35 5.42 ± 0.36 5.39 ± 0.31 5.45 ± 0.29 5.37 ± 0.40 




1.63 ± 1.99 1.79 ± 1.87 2.15 ± 0.24 2.13 ± 1.97 1.56 ± 1.35 
 PL 1.81 ± 1.93 1.80 ± 1.87 1.73 ± 1.73 1.29 ± 1.14 1.71 ± 1.31 
MC, Montmorency cherry group (n=10); PL, placebo group (n=10); Pre, pre-exercise; RF, 477 
rectus femoris; VL, vastus lateralis; GM, medial head of the gastrocnemius; PPT, pain pressure 478 
threshold; CMJ, countermovement jump; RSI, reactive strength index; MVC, maximal 479 




Figure 1. Muscle soreness (DOMS) post exercise-induced muscle damage in the Montmorency 483 
cherry (MC) (n=10) and placebo (PL) (n=10) groups. Values presented as mean ± SD.  484 
 25 
 485 
Figure 2. Percentage relative to pre-exercise (Pre) countermovement jump height (CMJ) post 486 
exercise-induced muscle damage in the Montmorency cherry (MC) (n=10) and placebo (PL) 487 
(n=10) groups. Values presented as mean ± SD. *denotes significantly higher CMJ in MC 488 
group. Significance at p<0.05. 489 
  490 
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 491 
Figure 3. Total creatine kinase (CK) at baseline pre-supplementation (BL), before (Pre) and 492 
post exercise-induced muscle damage in the Montmorency cherry (MC) (n=10) and placebo 493 
(PL) groups (n=10). Values presented as mean ± SD.  494 
